All In MedTech

Device Trial Radar · NCT02766543

Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer

Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study

Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Actual

Start

Sep 21, 2016

Primary completion

Feb 28, 2019

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Profound Medical Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 9, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multi-center, single-arm study, planned in 150 patients. The primary objective of the study is to further evaluate the safety and efficacy of a magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system (TULSA-PRO) intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • MRI-guided Transurethral Ultrasound AblationDevice

    Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoint - Incidence of treatment-emergent adverse eventsTime frame: 1 year

1 more outcomes with a free account

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.